Aptose Announces Pricing Of Underwritten Offering Of 4,912,280 Shares At $1.71 Per Share And Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Portfolio Pulse from Benzinga Newsdesk
Aptose Biosciences Inc. has priced an underwritten public offering of 4,912,280 shares at $1.71 each, with warrants included, aiming to raise approximately $8.4 million. Additionally, Aptose has arranged a $4 million private placement with Hanmi Pharmaceutical.
January 26, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aptose Biosciences has announced a public offering and a private placement which may dilute current shareholders but provide capital for operations.
The announcement of a new share offering typically leads to dilution of existing shares, which can cause a short-term negative impact on the stock price. The capital raised may benefit the company in the long term, but the immediate effect is often a decrease in share value due to the increase in supply of shares and the price set below the current market price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100